PharmaLex merger with MAP Group expands integrated market access expertise

PharmaLex merger with MAP Group expands integrated market access expertise  

Merger extends reach in key Italian marketplace and broadens market access expertise 

Frankfurt, Germany – January 18th 2022: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medical device industries worldwide, has announced a merger with MAP Group, Italy’s leading provider of market access services. 

Founded in 2010 by Elena Paola Lanati, MAP Group comprises three companies: MA Provider, MAPCOM Consulting and 3P Solution, which together deliver high-quality expertise across the product life cycle -- from negotiation strategy, to local market access, to market launch. 

MAP Group’s staff of more than 70 experts support a large number of new drugs for market entry in Italy, providing integrated market access, communication and educational services. The group specializes in highly innovative products, including advanced therapeutic medicinal products (ATMPs) being developed for rare diseases and oncology. The MAP Group is a leading member of ATMP Forum, a virtual organization established in 2017 to allow stakeholders to discuss issues related to ATMP development.  

“The merger with PharmaLex perfectly complements our service offerings by leveraging our strong local market knowledge and expertise while providing our clients with broader reach across Europe,” said Ms. Paola Lanati, will continue in the role of MAP Group CEO. ‘’We share common principles and values with PharmaLex, in particular to help our clients navigate an increasingly complex legislative and commercial marketplace. In addition, the merger with PharmaLex provides an opportunity for our talented people to expand their careers in a broader global marketplace.”  

“We are delighted to welcome the MAP Group team to the PharmaLex Group, and we are excited about the opportunity that the merger gives us to further expand our offerings in market access, brand communications and educational services,” said PharmaLex CEO Dr. Thomas Dobmeyer. ““The merger also enables us to extend our footprint in the important Italian marketplace, adding to our strong existing team in Milan, which provides regulatory, safety and quality services to local clients. PharmaLex first established an office in Italy 2017 and has since built a strong local footprint. Through the merger with the MAP Group, we are further strengthening our team, allowing us to support clients throughout the product lifecycle in order to deliver exceptional, tailor-made results.”